Adamantiades‐Behçet's disease (Behçet's disease) and COVID‐19.

The authors acknowledge the contribution of Prof. Dorian O. Haskard, National Heart and Lung Institute, Imperial College London, Hammersmith Campus, London, UK during the consensus procedure and thank the Associazione Sindrome e Malattia di Behçet e Behçet-like odv, Dr. Andreas Altenburg and Sophie den Otter for support on data collection. Two patients were admitted to the ICU and a patient, not been on treatment for ABD before getting COVID-19, died.9 COVID-19 symptoms were mild in the nine patients who survived, and three patients reported exacerbations of their ABD-associated oral ulcers or arthralgia. Moreover, among 2135 consecutive COVID-19 patients presented to the Hospital Clínic (Barcelona, Spain), four (0.19%) were co-diagnosed with ABD and three were hospitalized.7 In all four patients, ABD activity during the first COVID-19 symptoms was low. [Extracted from the article]